160 related articles for article (PubMed ID: 16969674)
1. [Cluster immunotherapy in allergic rhinoconjunctivitis: review of a new therapeutic approach].
Pfaar O; Klimek L
Hautarzt; 2006 Oct; 57(10):875-80. PubMed ID: 16969674
[TBL] [Abstract][Full Text] [Related]
2. [Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)].
Hansen I; Hörmann K; Stuck BA; Schneider-Gêne S; Mösges R; Klimek L
Laryngorhinootologie; 2003 Aug; 82(8):558-63. PubMed ID: 12915987
[TBL] [Abstract][Full Text] [Related]
3. Safety aspects of Cluster immunotherapy with semi-depot allergen extracts in seasonal allergic rhinoconjunctivitis.
Pfaar O; Mösges R; Hörmann K; Klimek L
Eur Arch Otorhinolaryngol; 2010 Feb; 267(2):245-50. PubMed ID: 19756683
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy with allergen extracts for allergic rhinitis].
Riechelmann H
HNO; 2005 Jun; 53(6):517-20, 522-6, 528-30. PubMed ID: 15915345
[TBL] [Abstract][Full Text] [Related]
5. Sublingual immunotherapy for allergic rhinoconjunctivitis--the seeming and the real.
Reider N
Int Arch Allergy Immunol; 2005 Jul; 137(3):181-6. PubMed ID: 15947473
[TBL] [Abstract][Full Text] [Related]
6. Sublingual immunotherapy in patients with allergic rhinoconjunctivitis caused by ragweed pollen.
Skoner D; Gentile D; Bush R; Fasano MB; McLaughlin A; Esch RE
J Allergy Clin Immunol; 2010 Mar; 125(3):660-6, 666.e1-666.e4. PubMed ID: 20153030
[TBL] [Abstract][Full Text] [Related]
7. [Cluster immunotherapy of persistent allergic rhinoconjunctivitis. Safety aspects of induction therapy with mite depot allergen preparations].
Pfaar O; Mösges R; Hörmann K; Klimek L
HNO; 2009 Nov; 57(11):1099-105. PubMed ID: 19585090
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
9. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts.
Casanovas M; Martín R; Jiménez C; Caballero R; Fernández-Caldas E
Int Arch Allergy Immunol; 2006; 139(2):153-8. PubMed ID: 16374026
[TBL] [Abstract][Full Text] [Related]
10. Allergy--current insights into prevention and diagnostic workup of immediate-type allergy and treatment of allergic rhinoconjunctivitis.
Brehler R; Stöcker B; Grundmann S
J Dtsch Dermatol Ges; 2015 Aug; 13(8):747-62; quiz 763-4. PubMed ID: 26213811
[TBL] [Abstract][Full Text] [Related]
11. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus.
Tabar AI; Echechipía S; García BE; Olaguibel JM; Lizaso MT; Gómez B; Aldunate MT; Martin S; Marcotegui F
J Allergy Clin Immunol; 2005 Jul; 116(1):109-18. PubMed ID: 15990782
[TBL] [Abstract][Full Text] [Related]
12. [Current recommendations for the use of SCIT and SLIT].
Lee H; Kleine-Tebbe J; Zuberbier T; Worm M
Hautarzt; 2006 Oct; 57(10):860-6. PubMed ID: 16964477
[TBL] [Abstract][Full Text] [Related]
13. Multiple daily administrations of low-dose sublingual immunotherapy in allergic rhinoconjunctivitis.
Bordignon V; Burastero SE
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):158-63. PubMed ID: 16937744
[TBL] [Abstract][Full Text] [Related]
14. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
15. [Specific immunotherapy in the treatment of atopic dermatitis].
Niebuhr M; Kapp A; Werfel T
Hautarzt; 2007 Mar; 58(3):232-6. PubMed ID: 17103200
[TBL] [Abstract][Full Text] [Related]
16. [Vaccination with allergens in children].
Demoly P; Dhivert-Donnadieu H; Bousquet J
Allerg Immunol (Paris); 2000 Dec; 32(10):397-401. PubMed ID: 11209473
[TBL] [Abstract][Full Text] [Related]
17. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy?
Senti G; von Moos S; Kündig TM
Allergy; 2011 Jun; 66(6):798-809. PubMed ID: 21518374
[TBL] [Abstract][Full Text] [Related]
18. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
19. Accelerated immunotherapy schedules: review of efficacy and safety.
Cox L
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):126-37; quiz 137-40, 202. PubMed ID: 16937741
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of cluster and conventional immunotherapy schedules with dermatophagoides pteronyssinus in the treatment of persistent allergic rhinitis.
Zhang L; Wang C; Han D; Wang X; Zhao Y; Liu J
Int Arch Allergy Immunol; 2009; 148(2):161-9. PubMed ID: 18802361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
